Literature DB >> 20221974

[Atrial fibrillation--epidemiologic, economic and individual burden of disease].

B Brüggenjürgen1, T Reinhold, D McBride, S N Willich.   

Abstract

Atrial fibrillation (AF) is the most frequent cardiac arrhythmia. AF affects especially the elderly. The incidence rises with increasing age to over 15% for those over 90 years old. AF is a risk factor for systemic embolism and ischemic stroke. Stroke with AF is more severe with regard to neurologic impairment. In the management of AF an anticoagulation is essential. However, only half of the patients benefit from anticoagulation in therapeutic target ranges. Costs associated with AF accrue to 660 to 924 Mio Euro in Germany with hospitalization being the major cost contributor. Management of stroke patients with AF is at 3000 Euro higher compared to those patients without AF. AF has an impact on patients' wellbeing and impairs patients' quality of life, particularly the symptomatic form. With an increasing ageing of the society it is suggested to ensure that care management for patients with AF will be optimized. Georg Thieme Verlag KG Stuttgart New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221974     DOI: 10.1055/s-0030-1249204

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation.

Authors:  Bernd Brüggenjürgen; Stefan Kohler; Nadja Ezzat; Thomas Reinhold; Stefan N Willich
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

2.  Improving performance of 3D speckle tracking in arterial hypertension and paroxysmal atrial fibrillation by using novel strain parameters.

Authors:  G Esposito; P Piras; A Evangelista; V Nuzzi; P Nardinocchi; G Pannarale; C Torromeo; P E Puddu
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.379

3.  Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.

Authors:  Vivek Y Reddy; Ronald L Akehurst; Shannon O Armstrong; Stacey L Amorosi; Nic Brereton; Deanna S Hertz; David R Holmes
Journal:  Europace       Date:  2016-02-02       Impact factor: 5.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.